ABOUT US
We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases.
Our lead program is our CardiAMP® autologous mononuclear cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
We are completing data monitoring for final data lock in the randomized double blind placebo procedure controlled CardiAMP Heart Failure Trial and anticipate results in Q1 2025. In parallel, we are actively enrolling in the CardiAMP Heart Failure II Trial.
To learn more about the CardiAMP Heart Failure studies and see if you or someone you may know might be eligible for the CardiAMP Heart Failure II Trial please click on the trial link below.
Discover us
Science
We work with our physicians and scientist collaborators to publish preclinical and clinical scientific studies performed to better understand our cellular medicine candidates and to provide evidence to support their approval and usage clinically for the benefit of patients.
Click here to see our most recent CardiAMP Heart Failure Trial data presented at Technology and Heart Failure Therapeutics 2024.
Pipeline
CALL US NOW
EMAIL US NOW